Novo Nordisk A/S
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 11 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | David Moore | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, US Operations | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (acquisition of shares in accordance with the recruitment package) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 0.00 | 18,634 | |||||
| d) | Aggregated information
| 18,634 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2025-11-10 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | David Moore | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, US Operations | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 297.95 | 8,160 | |||||
| d) | Aggregated information
| 8,160 shares DKK 2,431,301.74 | ||||
| e) | Date of the transaction | 2025-11-10 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com | Alex Bruce +45 34 44 26 13 axeu@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 33 / 2025
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Solar A/S11.11.2025 17:01:26 CET | Press release
Solar A/S: No. 12 2025 Solar A/S launches offering of up to 646,000 new B-shares in a directed issue and private placement
Solar A/S11.11.2025 17:01:26 CET | Pressemeddelelse
Solar A/S: Nr. 12 2025 Solar A/S lancerer udbud af op til 646.000 nye B-aktier i en rettet emission og privat placering
Rockwool A/S11.11.2025 16:25:47 CET | Pressemeddelelse
ROCKWOOL nedjusterer forventningen til EBIT-margin for hele året 2025
ROCKWOOL A/S11.11.2025 16:25:47 CET | Press release
ROCKWOOL adjusts outlook for full-year earnings for 2025
HSBC Continental Europe11.11.2025 15:58:42 CET | Press release
HSBC Continental Europe: Pre Stabilisation Notice
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom